Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease (Q38923188)

7 September 2017

1 reference

title

Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease (English)

1 reference

7 September 2017

0 references

1

Lesley J Scott

1 reference

7 September 2017

9 August 2016

1 reference

7 September 2017

1 reference

7 September 2017

76

1 reference

7 September 2017

13

1 reference

7 September 2017

1301-1312

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-016-0626-8

7 September 2017

0 references

cites work

The global economic burden of dengue: a systematic analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Tackling dengue fever: Current status and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

A comparative study on active and passive epidemiological surveillance for dengue in five countries of Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Epidemiological trends of dengue disease in Mexico (2000-2011): a systematic literature search and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Epidemiology of dengue disease in the Philippines (2000-2011): a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Epidemiology of dengue disease in Malaysia (2000-2012): a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Recent epidemiological trends of dengue in the French territories of the Americas (2000-2012): a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Epidemiological trends of dengue disease in Thailand (2000-2011): a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Epidemiological trends of dengue disease in Colombia (2000-2011): a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

The global distribution and burden of dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

New insights into the immunopathology and control of dengue virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Evaluation of diagnostic tests: dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Symptomatic Dengue in Children in 10 Asian and Latin American Countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Vaccination Against Dengue: Challenges and Current Developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur's tetravalent CYD dengue vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Efficacy of a tetravalent dengue vaccine in children in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Immunogenicity of sanofi pasteur tetravalent dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

A critical assessment of vector control for dengue prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Dengue vaccine: hypotheses to understand CYD-TDV-induced protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Potential opportunities and perils of imperfect dengue vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Current issues in the economics of vaccination against dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Dengue vaccines: dawning at last?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0626-8

Vector dynamics and transmission of dengue virus: implications for dengue surveillance and prevention strategies: vector dynamics and dengue prevention

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27506852

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27506852

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-016-0626-8

1 reference

PubMed ID

27506852

Dimensions Publication ID

7 September 2017

0 references

1 reference

PubMed ID

27506852